Kura Oncology (KURA)
(Delayed Data from NSDQ)
$20.95 USD
-0.13 (-0.62%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $20.95 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Brokerage Reports
0 items in cart
Kura Oncology, Inc. [KURA]
Reports for Purchase
Showing records 1 - 20 ( 269 total )
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KURA 091624
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology- ESMO 2024 Abstract Titles for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
2Q24 Results; Each Program Firing on All Cylinders; KOMET-001 Topline Data Expected Early 2025
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Ziftomenib Expands Into Solid Tumors; IND Cleared for Upcoming GIST Phase 1 Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Enter Metabolic Indications; ADA Underscores Ziftomenib?s Potential for Glycemic Control in T2D
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Where the Brook Is Deep; State of Acute Myeloid Leukemia Treatment
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Enrollment Wrap-Up for Pivotal KOMET-001 Phase 2 Trial; Top-Line Data Expected Early 2025
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Results; Enrollments on Track Across Programs; Ziftomenib to Pursue Solid Tumor IND Application in 2H24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
No Surprise Here; Ziftomenib Receives BTD in r/r NPM1-Mutant AML
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
FIT-001 Phase 1 Trial With KO-2806 Expands as First ccRCC Patient Dosed In Combo Studies
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
2023 Results; Ziftomenib Continues to March Onward; Momentum Is High for Clinical Program Developments in 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials; Zifto Flies into Additional Settings in KOMET-008
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Menin Inhibitors Carving Out a Niche in Leukemias: Rationale, Opportunities, and Candidates
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J